Subba Vanga, MD
Interventional Cardiology · Conyers, GANPI 1265698013
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 161 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by Novartis at 24.4% of the total. That places this record below the midpoint for interventional cardiology clinicians in GA, where the typical reported total is $7,640.
Across 161 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$901
- Amgen$365
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$268
- Boston Scientific$253
- Boehringer Ingelheim$249
- Merck$200
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,684100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 38 | $901 |
| Amgen | 22 | $365 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $268 |
| Boston Scientific | 10 | $253 |
| Boehringer Ingelheim | 10 | $249 |
| Merck | 9 | $200 |
| Pfizer | 8 | $157 |
| Edwards Lifesciences | 5 | $144 |
| AstraZeneca | 6 | $114 |
| E.r. Squibb & Sons, L.L.C. | 5 | $114 |
| Cvrx, Inc. | 6 | $112 |
| Alnylam Pharmaceuticals Inc. | 4 | $102 |
| Scpharmaceuticals Inc. | 3 | $88 |
| Medtronic(2 entities) | 3 | $78 |
| Intuitive Surgical | 1 | $72 |
| Inari Medical, Inc. | 1 | $60 |
| Johnson & Johnson | 3 | $50 |
| W. L. Gore & Associates, Inc. | 1 | $35 |
| Abiomed | 1 | $28 |
| Imperative Care, Inc | 1 | $28 |
| Silk Road Medical, Inc. | 1 | $26 |
| Abbott | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| BD | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Heartflow, Inc. | 1 | $16 |
| Biosense Webster, Inc. | 1 | $15 |
How this compares
$3,684 in reported general payments places this provider in the 25th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 190 | $193,162 |
| XareltoRivaroxaban | 46 | $64,272 |
| EntrestoSacubitril/Valsartan | 25 | $40,815 |
| Repatha SureclickEvolocumab | 19 | $27,368 |
| BrilintaTicagrelor | 15 | $12,681 |
| Metoprolol Succinate | 203 | $2,510 |
| Atorvastatin Calcium | 221 | $1,717 |
| Losartan Potassium | 159 | $1,142 |
| Carvedilol | 109 | $1,064 |
| Rosuvastatin Calcium | 65 | $846 |
| ClopidogrelClopidogrel Bisulfate | 116 | $839 |
| Hydralazine Hcl | 50 | $602 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 44 | $595 |
| Amlodipine Besylate | 95 | $551 |
| Potassium Chloride | 13 | $416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $157 | $193,162190 claims |
| Johnson & JohnsonXarelto | $50 | $64,27246 claims |
| NovartisEntresto | $901 | $40,81525 claims |
| AstraZenecaBrilinta | $114 | $12,68115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Conyers
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
- Katherine KunkelAtlanta$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.